Leerink Partnrs Issues Positive Estimate for BOLT Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Equities research analysts at Leerink Partnrs increased their Q1 2025 EPS estimates for shares of Bolt Biotherapeutics in a research report issued to clients and investors on Tuesday, March 25th. Leerink Partnrs analyst D. Graybosch now expects that the company will post earnings of ($0.34) per share for the quarter, up from their previous estimate of ($0.41). The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. Leerink Partnrs also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.35) EPS, Q4 2025 earnings at ($0.35) EPS, FY2025 earnings at ($1.38) EPS, FY2026 earnings at ($0.83) EPS, FY2027 earnings at ($0.42) EPS, FY2028 earnings at ($0.30) EPS and FY2029 earnings at ($0.23) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Monday, March 24th. The company reported ($0.38) EPS for the quarter, hitting the consensus estimate of ($0.38). Bolt Biotherapeutics had a negative net margin of 665.56% and a negative return on equity of 69.46%. The firm had revenue of $0.01 million during the quarter, compared to analysts’ expectations of $0.79 million.

BOLT has been the topic of a number of other reports. HC Wainwright reissued a “neutral” rating on shares of Bolt Biotherapeutics in a research note on Tuesday, March 25th. Stifel Nicolaus decreased their target price on shares of Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research report on Tuesday, March 25th. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $1.13.

Bolt Biotherapeutics Price Performance

BOLT stock opened at $0.43 on Friday. The stock has a market capitalization of $16.29 million, a price-to-earnings ratio of -0.25 and a beta of 0.94. The stock’s fifty day simple moving average is $0.47 and its 200-day simple moving average is $0.55. Bolt Biotherapeutics has a 52-week low of $0.38 and a 52-week high of $1.56. The company has a quick ratio of 3.16, a current ratio of 3.16 and a debt-to-equity ratio of 0.21.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in BOLT. Citadel Advisors LLC acquired a new stake in Bolt Biotherapeutics during the fourth quarter worth about $42,000. Velan Capital Investment Management LP acquired a new position in shares of Bolt Biotherapeutics in the 4th quarter valued at about $27,000. Squarepoint Ops LLC purchased a new stake in shares of Bolt Biotherapeutics during the 4th quarter worth about $26,000. Millennium Management LLC acquired a new stake in Bolt Biotherapeutics during the 4th quarter worth approximately $25,000. Finally, FMR LLC raised its holdings in Bolt Biotherapeutics by 33.2% in the third quarter. FMR LLC now owns 115,386 shares of the company’s stock valued at $75,000 after buying an additional 28,773 shares during the period. 86.70% of the stock is owned by hedge funds and other institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.